Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
  • C07H7/04—Carbocyclic radicals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives

Definitions

• diabetes mellitus According to the World Health Organization, approximately 150 million people worldwide have diabetes mellitus. The two principal forms of diabetes are type 1 diabetes, in which the pancreas fails to produce insulin, and type 2 diabetes, in which the body fails to respond properly to the insulin produced (insulin resistance). Accounting for about 90% of all diabetes cases, type 2 diabetes is by far the most common. In both types of diabetes, the absence of insulin action or proper response to insulin results in elevated levels of serum glucose (hyperglycemia). Serious complications associated with diabetes include retinopathy (leading to visual impairment or blindness), cardiovascular disease, nephropathy, neuropathy, ulcers and diabetic foot disease.
• Type 1 diabetes currently require insulin therapy. While in many cases type 2 diabetes can be managed with diet and exercise, drug intervention also frequently is required. Besides insulin, which is needed by about one-third of patients with type 2 diabetes, current antidiabetic therapies include biguanides (which decrease glucose production in the liver and increase sensitivity to insulin), sulfonylureas and meglitinides (which stimulate insulin production), alpha-glucosidase inhibitors (which slow starch absorption and glucose production), and thiazolidinediones (which increase insulin sensitivity). These medicines are often used in combination, and even then may not provide adequate glycemic control or may produce undesired side effects.
• biguanides which decrease glucose production in the liver and increase sensitivity to insulin
• sulfonylureas and meglitinides which stimulate insulin production
• alpha-glucosidase inhibitors which slow starch absorption and glucose production
• thiazolidinediones which increase insulin sensitivity
• Such side effects include lactic acidosis (biguanides), hypoglycemia (sulfonylureas), and edema and weight gain (thiazolidinediones). Therefore, new antidiabetic agents providing improved glycemic control and lacking these adverse effects are highly desired.
• SGLT glucose transport system of the kidneys.
• Cellular glucose transport is conducted by either facilitative ("passive") glucose transporters (GLUTs) or sodium-dependent (“active”) glucose cotransporters (SGLTs).
• GLUTs facilitative
• active sodium-dependent
• SGLTl is found predominantly in the intestinal brush border, while SGLT2 is localized in the renal proximal tubule and is reportedly responsible for the majority of glucose reuptake by the kidneys.
• the present invention provides compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT.
• the invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.
• Figures 1-2 provide generic synthesis schemes for compounds of the invention.
• Figures 3-8 provide more specific synthesis schemes for compounds in the Examples below.
• halo means a monovalent halogen radical or atom selected from fluoro, chloro, bromo and iodo. Preferred halo groups are fluoro, chloro and bromo.
• suitable substituent means a chemically and pharmaceutically acceptable group, i.e., a moiety that does not significantly interfere with the preparation of or negate the efficacy of the inventive compounds.
• suitable substituents may be routinely chosen by those skilled in the art.
• Suitable substituents may be selected from the group consisting of halo, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, Ci-C 6 haloalkoxy, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkenyl, (C 3 -C 8 cycloalkyl)C r C 6 alkyl, (C 3 -C 8 cycloalkyl)C 2 -C 6 alkenyl, (C 3 -C 8 CyClOaUCyI)C 1 -C 6 alkoxy, C 3 -C 7 heterocycloalkyl, (C 3 -C 7 heterocycloalky ⁇ CrC ⁇ alkyl, (C 3 -C 7 heterocycloalkyl)C 2 -C 6 alkenyl, (C 3 -C 7 heterocycloalkyl)C]-C 6 alk
• alkyl alone or in combination refers to a monovalent saturated aliphatic hydrocarbon radical having the indicated number of carbon atoms.
• the radical may be a linear or branched chain and, where specified, optionally substituted with one to three suitable substituents as defined above.
• alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, n-pentyl, n- hexyl, isopropyl, isobutyl, isopentyl, amyl, sec-butyl, tert-butyl, tert-pentyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-dodecyl, n-tetradecyl, n-hexadecyl, n-octadecyl, n-eicosyl and the like.
• Preferred alkyl groups include methyl, ethyl, n-propyl and isopropyl.
• Preferred optional suitable substituents include halo, methoxy, ethoxy, cyano, m ' tro and amino.
• alkenyl alone or in combination refers to a monovalent aliphatic hydrocarbon radical having the indicated number of carbon atoms and at least one carbon-carbon double bond.
• the radical may be a linear or branched chain, in the E or Z form, and where specified, optionally substituted with one to three suitable substituents as defined above.
• alkenyl groups include, but are not limited to, vinyl, 1-propenyl, 2-propenyl, isopropenyl, 1-butenyl, 2- butenyl, isobutenyl, 2-methyl- 1-propenyl, 1-pentenyl, 2-pentenyl, 4-methyl-2-pentenyl, 1,3- pentadienyl, 2,4-pentadienyl, 1,3-butadienyl and the like.
• Preferred alkenyl groups include vinyl, 1-propenyl and 2-propenyl.
• Preferred optional suitable substituents include halo, methoxy, ethoxy, cyano, nitro and amino.
• alkynyl alone or in combination refers to a monovalent aliphatic hydrocarbon radical having the indicated number of carbon atoms and at least one carbon-carbon triple bond.
• the radical may be a linear or branched chain and, where specified, optionally substituted with one to three suitable substituents as defined above.
• alkynyl groups include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, 2- pentynyl, 3-methyl- 1-pentynyl, 3-pentynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl and the like.
• Preferred alkynyl groups include ethynyl, 1-propynyl and 2-propynyl.
• Preferred optional suitable substituents include halo, methoxy, ethoxy, cyano, nitro and amino.
• cycloalkyl alone or in combination refers to a monovalent alicyclic saturated hydrocarbon radical having three or more carbons forming a carbocyclic ring and, where specified, optionally substituted with one to three suitable substituents as defined above.
• Illustrative examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl and the like.
• Preferred optional suitable substituents include halo, methyl, ethyl, methoxy, ethoxy, cyano, nitro and amino.
• cycloalkenyl alone or in combination refers to a monovalent alicyclic hydrocarbon radical having three or more carbons forming a carbocyclic ring and at least one carbon-carbon double bond and, where specified, optionally substituted with one to three suitable substituents as defined above.
• Illustrative examples of cycloalkenyl groups include, but are not limited to, cyclopentenyl, cyclohexenyl and the like.
• Preferred optional suitable substituents include halo, methyl, ethyl, methoxy, ethoxy, cyano, nitro and amino.
• alkylene alkenylene
• cycloalkylene cycloalkenylene
• cycloalkenylene refer to a divalent hydrocarbon radical that is formed by removal of a hydrogen atom from an alkyl, alkenyl, cycloalkyl or cycloalkenyl radical, respectively, as such terms are defined above.
• (C 3 -Ci 0 cycloalkylene)(Ci-C 6 alkylene) refers to a divalent hydrocarbon radical that is formed by bonding a C 3 -Ci O cycloalkylene radical with Ci-C 6 alkylene radical, as such terms are defined above.
• aryl alone or in combination refers to a monovalent aromatic hydrocarbon radical having six to ten carbon atoms forming a carbocyclic ring and, where specified, optionally substituted with one to three suitable substituents as defined above.
• aryl groups include, but are not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl and the like.
• Preferred aryl groups are phenyl and naphthyl, optionally mono- or disubstituted by identical or different suitable substituents selected from halo, cyano, Ci-C 3 alkyl, C 3 -C 6 cycloalkyl, difluoromethyl, trifiuoromethyl, Ci-C 3 alkoxy, difluoromethoxy and trifluoromethoxy.
• heterocycloalkyl alone or in combination refers to a cycloalkyl group as defined above in which one or more carbons in the ring is replaced by a heteroatom selected from N, S and O.
• heterocycloalkyl groups include, but are not limited to, pyrrolidinyl, tetrahydrofuranyl, piperazinyl, tetrahydropyranyl, and the like.
• heteroaryl alone or in combination refers to a monovalent aromatic heterocyclic radical having two to nine carbons and one to four heteroatoms selected from N, S and O forming a five- to ten-membered monocyclic or fused bicyclic ring and, where specified, optionally substituted with one to three suitable substituents as defined above.
• heteroaryl groups include, but are not limited to, pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, triazinyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, benzotriazinyl, benzimidazolyl, benzopyrazolyl, benzotriazolyl, benzisoxazolyl, isobenzofuryl, isoindolyl, indolizinyl, thienopyridinyl, thienopyrimidinyl, pyrazolopyrimidinyl, imidazopyridines, benzothiaxolyl, benzofuranyl, benzothienyl, indolyl, isothiazolyl, pyrazolyl, indazolyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl,
• Five- or six-membered monocyclic heteroaryl rings include: pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, triazinyl, isothiazolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyrrolyl, thiazolyl, furyl, thienyl and the like .
• Eight- to ten-membered bicyclic heteroaryl rings having one to four heteroatoms include: quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, benzotriazinyl, benzimidazolyl, benzopyrazolyl, benzotriazolyl, benzisoxazolyl, isobenzofuryl, isoindolyl, indolizinyl, thienopyridinyl, thienopyrimidinyl, pyrazolopyrimidinyl, imidazopyridinyl, benzothiaxolyl, benzofuranyl, benzothienyl, indolyl, indazolyl, and the like.
• Preferred optional suitable substitutions include one or two identical or different substituents selected from halo, cyano, C 1 -C 3 alkyl, C 3 -C 6 cycloalkyl, difluoromethyl, trifluoromethyl, C 1 -C 3 alkoxy, difluoromethoxy and trifluoromethoxy.
• alkoxy and alkyloxy alone or in combination refer to an aliphatic radical of the form alkyl-O-, wherein alkyl is as defined above.
• alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tertiary butoxy, pentoxy, isopentoxy, neopentoxy, tertiary pentoxy, hexoxy, isohexoxy, heptoxy, octoxy and the like.
• Preferred alkoxy groups include methoxy and ethoxy.
• haloalkyl refers to an alkyl radical as described above substituted with one or more halogens.
• Illustrative examples of haloalkyl groups include, but are not limited to, chloromethyl, dichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trichloroethyl and the like.
• haloalkoxy refers to an alkoxy radical as described above substituted with one or more halogens.
• Illustrative examples of haloalkoxy groups include, but are not limited to, trifluoromethoxy, difiuoromethoxy and the like.
• aralkyl refers to an alkyl radical of one to six carbons as described above substituted with an aryl group as described above.
• heteroarylkyl refers to an alkyl radical of one to six carbons as described above substituted with a heteroaryl group as described above.
• aralkoxy refers to an alkoxy radical of one to six carbons as described above substituted with an aryl group as described above.
• heteroarylkoxy refers to an alkoxy radical of one to six carbons as described above substituted with a heteroaryl group as described above.
• carbamoyl refers to a monovalent radical of the form -C(O)NH(R), wherein R is hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 3 -C 6 cycloalkyl, or aryl as such terms are defined above.
• di-(d-C 3 alkyl)amino and "di-(Ci-C 6 alkyl)amino" alone or in combination refer to an amino group that is substituted with two groups independently selected from C 1 -C 3 alkyl or C 1 -C 6 alkyl, respectively.
• treating refers to delaying the onset of, retarding or reversing the progress of, or alleviating or preventing either the disease or condition to which the term applies, or one or more symptoms of such disease or condition.
• administering means oral administration, administration as a suppository, topical contact, intravenous, intraperitoneal, intramuscular, intralesional, intranasal or subcutaneous administration, or the implantation of a slow-release device, e.g., a mini-osmotic pump, to a subject.
• Administration is by any route including parenteral, and transmucosal (e.g., oral, nasal, vaginal, rectal, or transdermal).
• Parenteral administration includes, e.g., intravenous, intramuscular, intra-arteriole, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial.
• Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, and the like.
• prodrug refers to a precursor compound that, following administration, releases the biologically active compound in vivo via some chemical or physiological process (e.g., a prodrug on reaching physiological pH or through enzyme action is converted to the biologically active compound).
• a prodrug itself may either lack or possess the desired biological activity.
• the term "compound” refers to a molecule produced by any means including, without limitation, synthesis in vitro or generation in situ or in vivo.
• controlled release sustained release
• extended release extended release
• timed release any drug-containing formulation in which release of the drug is not immediate, i.e., with a “controlled release” formulation, oral administration does not result in immediate release of the drug into an absorption pool.
• immediate and nonimmediate release can be defined kinetically by reference to the following equation:
• the "absorption pool" represents a solution of the drug administered at a particular absorption site, and k r , k a and k e are first-order rate constants for (1) release of the drug from the formulation, (2) absorption, and (3) elimination, respectively.
• the rate constant for drug release k r is far greater than the absorption rate constant k a .
• the opposite is true, i.e., k r «k a , such that the rate of release of drug from the dosage form is the rate-limiting step in the delivery of the drug to the target area.
• sustained release and extended release are used in their conventional sense to refer to a drug formulation that provides for gradual release of a drug over an extended period of time, for example, 12 hours or more, and that preferably, although not necessarily, results in substantially constant blood levels of a drug over an extended time period.
• delayed release refers to a pharmaceutical preparation that passes through the stomach intact and dissolves in the small intestine.
• the present invention provides compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT, preferably SGLT2. Some compounds according to the present invention also have an inhibitory effect on sodium-dependent glucose cotransporter SGLTl. Owing to their ability to inhibit SGLT, the compounds of the present invention are suitable for the treatment and/or prevention of any and all conditions and diseases that are affected by inhibition of SGLT activity, particularly SGLT2 activity.
• the compounds of the present invention are suitable for the prevention and treatment of diseases and conditions, particularly metabolic disorders, including but not limited to type 1 and type 2 diabetes mellitus, hyperglycemia, diabetic complications (such as retinopathy, nephropathy [e.g., progressive renal disease], neuropathy, ulcers, micro- and macroangiopathies, and diabetic foot disease), insulin resistance, metabolic syndrome (Syndrome X), hyperinsulinemia, hypertension, hyperuricemia, obesity, edema, dyslipidemia, chronic heart failure, atherosclerosis and related diseases.
• metabolic disorders including but not limited to type 1 and type 2 diabetes mellitus, hyperglycemia, diabetic complications (such as retinopathy, nephropathy [e.g., progressive renal disease], neuropathy, ulcers, micro- and macroangiopathies, and diabetic foot disease), insulin resistance, metabolic syndrome (Syndrome X), hyperinsulinemia, hypertension, hyperuricemia, obesity, edema, dyslipidemia, chronic heart failure,
• the present invention also provides pharmaceutically acceptable salts and prodrugs of compounds according to the present invention.
• the present invention further provides pharmaceutical compositions comprising an effective amount of a compound or mixture of compounds according to the present invention, or a pharmaceutically acceptable salt or prodrug thereof, in a pharmaceutically acceptable carrier.
• the present invention further provides synthetic intermediates and processes for preparing the compounds of the present invention.
• the present invention also provides methods of using the compounds according to the present invention, independently or in combination with other therapeutic agents, for treating diseases and conditions which may be affected by SGLT inhibition. [0043] The present invention also provides methods of using the compounds according to the present invention for the preparation of a medicament for treating diseases and conditions which may be affected by SGLT inhibition.
• the present invention provides for compounds of Formula I:
• A represents oxygen; NH; methylene; or a single bond
• Q is selected from one of the following formulae Q 1 to Q 4 ;
• Z represents oxygen; sulfur; SO; SO 2 ; 1,1-cyclopropylene; carbonyl; or methylene optionally substituted with one to two substituents independently selected from halo, hydroxy, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 3 -C 6 cycloalkyl and C 3 -C 6 cycloalkyloxy;
• R 1 , R 2 and R 3 each independently represent hydrogen, halo, hydroxy, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C] O cycloalkyl, C 5 -C 10 cycloalkenyl, C 1 -C 6 alkyloxy, C 3 -C 10 cycloalkyloxy, cyano, amino or nitro, wherein alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl groups or portions optionally may be partly or completely fluorinated and may be mono- or disubstituted by identical or different substituents selected from chlorine, hydroxy, C 1 -C 3 alkoxy and C 1 -C 3 alkyl, and in cycloalkyl and cycloalkenyl groups or portions one or two methylene groups are optionally replaced independently of one another by NR a , O, S, CO
• R 1 and R 2 may be joined together such that R 1 and R 2 together form a C 3 -C 5 alkylene, C 3 -C 5 alkenylene or butadienylene bridge, which may be partly or completely fluorinated and may be mono- or disubstituted by identical or different substituents selected from chlorine, hydroxy, C 1 -C 3 alkoxy and Ci-C 3 alkyl, and wherein one or two methylene groups are optionally replaced independently of one another by O, S, CO, SO, SO 2 or NR a , and wherein one or two methyne groups optionally may be replaced by N;
• R 4 independently represents hydrogen, halo, cyano, nitro, amino, hydroxy, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -Ci 0 cycloalkyl, C 5 -Ci 0 cycloalkenyl, C 1 -C 6 alkyloxy, C 3 -C 10 cycloalkyloxy, (C 1 -C 6 alkyloxy)C 1 -C 6 alkyloxy, C 5 -C 7 cycloalkenyloxy, aryl, heteroaryl, aryloxy, heteroaryloxy, (C 2 -C 4 alkenyl)Ci-C 3 alkyloxy, (C 2 -C 4 alkynyl)Ci-C 3 alkyloxy, (aryl)Ci-C 3 alkyloxy, (heteroaryl)Ci-C 3 alkyloxy, (C 3 -Ci 0
• R 5 and R 6 each independently represent hydrogen, halo, cyano, nitro, hydroxy, C 1 - C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 10 cycloalkyl, C 1 -C 3 alkyloxy or C 3 -C 10 cycloalkyloxy, wherein alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl groups or portions optionally may be partly or completely fluorinated and may be mono- or disubstituted by identical or different substituents selected from chlorine, hydroxy, C 1 -C 3 alkoxy and C 1 -C 3 alkyl, and in cycloalkyl and cycloalkenyl groups or portions one or two methylene groups are optionally replaced independently of one another by NR a , O, S, CO, SO or SO 2 , and one or two methyne groups optionally
• R 5 and R 6 are bound to two adjacent C atoms of the phenyl ring, R 5 and R 6 optionally may be joined together such that R 5 and R 6 together form a C 3 -C 5 alkylene, C 3 -C 5 alkenylene or butadienylene bridge, which may be partly or completely fluorinated and mono- or disubstituted by identical or different substituents selected from chlorine, hydroxy, C 1 -C 3 alkoxy and C 1 -C 3 alkyl, and wherein one or two methylene groups are optionally replaced independently of one another by O, S, CO, SO, SO 2 or NR a , and wherein one or two methyne groups may be replaced by N;
• R 7 , R 8 , R 9 and R 10 each independently represent hydroxy, (C 1 -C 18 alkyl)carbonyloxy, (C 1 -C 18 alkyl)oxycarbonyloxy, arylcarbonyloxy, aryl-(d-C 3 alkyl)carbonyloxy, (C 3 -C 10 cycloalkyl)carbonyloxy, hydrogen, halo, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, (C 3 -C 10 cycloalkyl)d-C 3 alkyl, (C 5 -C 7 cycloalkenyl)d-C 3 alkyl, (8TyI)C 1 -C 3 alkyl, (heteroaryl)Ci-C 3 alkyl, C 1 -C 6 alkyloxy, C 2 -C 6 alkenyloxy, C 2 -C 6 alkynyloxy, C 3 -C 10
• alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl groups or portions optionally may be partly or completely fluorinated and may be mono- or disubstituted by identical or different substituents selected from chlorine, hydroxy, C 1 -C 3 alkoxy and C 1 -C 3 alkyl, and in cycloalkyl and cycloalkenyl groups or portions one or two methylene groups are optionally replaced independently of one another by NR a , O, S, CO, SO or SO 2 ;
• R 10 and R 1 ! can be combined with the carbon atoms to which each is attached to form a five- to seven-membered fused cycloalkane or cycloalkene ring that is optionally partly or completely fluorinated and may be mono- or disubstituted by identical or different substituents selected from chlorine, hydroxy, C 1 -C 3 alkoxy and Ci-C 3 alkyl, and wherein in the cycloalkyl and cycloalkenyl rings one or two methylene groups are optionally replaced independently of one another by NR a , O, S, CO, SO or SO 2 ;
• R 11 and R 12 each independently represents hydrogen, hydroxy, halo, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C] 0 cycloalkyl, C 1 -C 6 alkyloxy, C 2 -C 6 alkenyloxy, C 2 -C 6 alkynyloxy or C 3 -C 6 cycloalkyloxy, wherein alkyl, alkenyl, alkynyl and cycloalkyl groups or portions optionally may be partly or completely fluorinated, or
• R 11 and R 12 optionally may be joined together such that R 11 and R 12 together with the carbon atom to which they are attached form a C 3 -C 7 spirocycloalkane ring which optionally may be partly or completely fluorinated and may be mono- or disubstituted by identical or different substituents selected from chlorine, hydroxy, Ci-C 3 alkoxy and C]-C 3 alkyl;
• R 10 or R 14 is halo or R 13 is other than hydrogen or R 4 is C 2 -C 6 alkynyl, C 3 -Ci 0 cycloalkyloxy, C 5 -C 7 cycloalkenyloxy, (C 3 -Ci 0 cycloalkyl)Ci-C 3 alkyloxy, (C 3 -C 7 cycloalkyl)C 3 -C 5 alkenyloxy, (C 3 -C 7 cycloalkyl)C 3 -C 5 alkynyloxy, (C 5 -Ci 0 cycloalkenyl)d-C 3 alkyloxy, (C 5 -C 8 cycloalkenyl)C 3 -C 5 alkenyloxy or (C 5 -C 8 cycloalkenyl)C 3 -C 5 alkynyloxy, or
• R 10 when Q is Q 2 and R 11 is hydrogen, then at least R 10 is halo or R 4 is C 2 -C 6 alkynyl, C 3 -C 10 cycloalkyloxy, C 5 -C 7 cycloalkenyloxy, (C 3 -Ci 0 cycloalkyl)d-C 3 alkyloxy, (C 3 -C 7 cycloalkyl)C 3 -C 5 alkenyloxy, (C 3 -C 7 cycloalkyl)C 3 -C 5 alkynyloxy, (C 5 -Ci 0 cycloalkenyl)Ci- C 3 alkyloxy, (C 5 -C 8 cycloalkenyl)C 3 -C 5 alkenyloxy or (C 5 -C 8 cycloalkenyl)C 3 -C 5 alkynyloxy, or
• R 10 when Q is Q 4 and R 11 is hydrogen, then at least R 10 is halo or R 13 is other than hydrogen or R 4 is C 2 -C 6 alkynyl, C 3 -C 10 cycloalkyloxy, C 5 -C 7 cycloalkenyloxy, (C 3 -C 10 cycloalkyl)C!-C 3 alkyloxy, (C 3 -C 7 cycloalkyl)C 3 -C 5 alkenyloxy, (C 3 -C 7 cycloalkyl)C 3 -C 5 alkynyloxy, (C 5 -C 10 cycloalkenyl)Ci-C 3 alkyloxy, (C 5 -C 8 cycloalkenyl)C 3 -C 5 alkenyloxy or (C 5 -C 8 cycloalkenyl)C 3 -C 5 alkynyloxy;
• R 13 and R 14 each independently represent hydrogen, hydroxy, halo, C 1 -C 6 alkyl, C 2 - C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 10 cycloalkyl, Ci-C 6 alkyloxy, C 2 -C 6 alkenyloxy, C 2 -C 6 alkynyloxy or C 3 -C 6 cycloalkyloxy, wherein alkyl, alkenyl, alkynyl and cycloalkyl groups or portions optionally may be partly or completely fluorinated;
• R 15 independently represents oxygen or CR b R c ;
• R a independently represents hydrogen, C 1 -C 4 alkyl or (Ci-C 4 alkyl)carbonyl, wherein alkyl groups or portions optionally may be partly or completely fluorinated;
• R b and R c each independently represent hydrogen, halo or C 1 -C 4 alkyl, wherein alkyl groups optionally may be partly or completely fluorinated.
• the present invention includes all tautomers and stereoisomers of compounds of Formula I, either in admixture or in pure or substantially pure form.
• the compounds of the present invention can have asymmetric centers at the carbon atoms, and therefore the compounds of Formula I can exist in diastereomeric or enantiomeric forms or mixtures thereof. All conformational isomers (e.g., cis and trans isomers) and all optical isomers (e.g., enantiomers and diastereomers), racemic, diastereomeric and other mixtures of such isomers, as well as solvates, hydrates, isomorphs, polymorphs and tautomers are within the scope of the present invention.
• Prodrugs of compounds of Formula I include, but are not limited to, carboxylate esters, carbonate esters, hemi-esters, phosphorus esters, nitro esters, sulfate esters, sulfoxides, amides, carbamates, azo compounds, phosphatides, glycosides, ethers, acetals, and ketals.
• Prodrug esters and carbonates may be formed, for example, by reacting one or more hydroxyl groups of compounds of Formula I with alkyl, alkoxy or aryl substituted acylating reagents using methods known to those of skill in the art to produce methyl carbonates, acetates, benzoates, pivalates and the like.
• prodrug esters of the compounds of the present invention include, but are not limited to, compounds of Formula I having a carboxyl moiety wherein the free hydrogen is replaced by Ci-C 4 alkyl, C 1 -C 7 alkanoyloxymethyl, 1 -((C i -C 5 )alkanoyloxy)ethyl, 1 -methyl- 1 -((C 1 -C 5 )alkanoyloxy)-ethyl, Ci-C 5 alkoxycarbonyloxymethyl, l-((Ci-C 5 )alkoxycarbonyloxy)ethyl, 1 -methyl- 1-((Ci- C 5 )alkoxycarbonyloxy)ethyl, N-((C i -C 5 )alkoxycarbonyl)aminomethyl, 1 -(N-((C i - C 5 )alkoxycarbonyl)amino)ethyl, 3-phthalidyl
• Oligopeptide modifications and biodegradable polymer derivatives are within the scope of the invention.
• Methods for selecting and preparing suitable prodrugs are provided, for example, in the following: T. Higuchi and V. Stella, "Prodrugs as Novel Delivery Systems,” Vol. 14, ACS Symposium Series, 1975; H. Bundgaard, “Design of Prodrugs,” Elsevier, 1985; and “Bioreversible Carriers in Drug Design,” ed. Edward Roche, American Pharmaceutical Association and Pergamon Press, 1987.
• the present invention also provides for the pharmaceutically acceptable salts of compounds of Formula I and prodrugs thereof.
• the acids that can be used as reagents to prepare the pharmaceutically acceptable acid addition salts of the basic compounds of this invention are those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions (such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate (1,1'- methylene-bis-2-hydroxy-3-naphthoate) salts).
• the bases that can be used as reagents to prepare the pharmaceutically acceptable base salts of the acidic compounds of the present invention are those that form non-toxic base salts with such compounds, including, but not limited to, those derived from pharmacologically acceptable cations such as alkali metal cations (e.g., potassium, lithium and sodium) and alkaline earth metal cations (e.g., calcium and magnesium), ammonium or water-soluble amine addition salts such as N- methylglucamine (meglumine), and the lower alkanolammonium and other base salts of pharmaceutically acceptable organic amines (e.g., methylamine, ethylamine, propylamine, dimethylamine, triethanolamine, diethylamine, t-butylamine, t-octylamine, trimethylamine, triethylamine, ethylenediamine, hydroxyethylamine, morpholine, piperazine, dehydroabietylamine, lysine and
• the present invention also includes isotopically-labeled compounds of Formula I, wherein one or more atoms are replaced by one or more atoms having specific atomic mass or mass numbers.
• isotopes that can be incorporated into compounds of the invention include, but are not limited to, isotopes of hydrogen, carbon, nitrogen, oxygen, fluorine, sulfur, and chlorine (such as 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 17 0, 18 F, 35 S and 36 Cl).
• Isotopically-labeled compounds of Formula I and prodrugs thereof, as well as isotopically- labeled, pharmaceutically acceptable salts of compounds of Formula I and prodrugs thereof, are within the scope of the present invention.
• Isotopically-labeled compounds of the present invention are useful in assays of the tissue distribution of the compounds and their prodrugs and metabolites; preferred isotopes for such assays include 3 H and 14 C.
• preferred isotopes for such assays include 3 H and 14 C.
• substitution with heavier isotopes, such as deuterium ( 2 H) can provide increased metabolic stability, which offers therapeutic advantages such as increased in vivo half-life or reduced dosage requirements.
• Isotopically-labeled compounds of this invention and prodrugs thereof can generally be prepared according to the methods described herein by substituting an isotopically-labeled reagent for a non-isotopically labeled reagent.
• A represents oxygen or a single bond. In particularly preferred embodiments, A represents a single bond.
• Z represents oxygen, sulfur, or methylene optionally substituted with one to two substituents independently selected from halo, hydroxy, Ci-C 6 alkyl, Ci-C 6 alkoxy, C 3 -C 6 cycloalkyl and C 3 -C 6 cycloalkyloxy. In particularly preferred embodiments, Z represents methylene.
• R 1 , R 2 and R 3 each independently represent hydrogen, halo, hydroxy, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -Ci 0 cycloalkyl, C 1 -C 6 alkyloxy, or cyano.
• R 1 , R 2 and R 3 each independently represent hydrogen, halo or C 1 -C 6 alkyl.
• R 1 represents hydrogen, halo or C 1 -C 6 alkyl and R 2 and R 3 both represent hydrogen.
• R 4 represents C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 1O cycloalkyl, Ci-C 6 alkyloxy, C 3 -C 10 cycloalkyloxy, (C 3 -Ci 0 cycloalkyl)Ci-C 3 alkyloxy, (C 3 -C 7 cycloalkyl)C 3 -C 5 alkenyloxy, or (C 3 -C 7 cycloalkyl)C 3 -C 5 alkynyloxy.
• R 5 and R 6 each independently represent hydrogen, halo, hydroxy, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -Ci 0 cycloalkyl, Ci-C 6 alkyloxy, or cyano.
• R 5 and R 6 each independently represent hydrogen, halo or Ci-C 6 alkyl. In more particularly preferred embodiments, R 5 and R 6 both represent hydrogen.
• R 7 , R 8 , R 9 and R 10 each independently represent hydroxy, halo, Ci-C 6 alkyl, Ci-C 6 alkyloxy, (C 3 -C 7 )cycloalkyloxy, aryloxy or (C 3 - C 7 )cycloalkyl-(Ci-C 3 )alkyloxy, wherein alkyl and cycloalkyl groups or portions may be partly or completely fluorinated.
• R 7 , R 8 , R 9 and R 10 each represent hydroxy.
• R 11 represents hydrogen or hydroxy.
• R 12 , R 13 and R 14 represent hydrogen.
• R 15 represents oxygen or CR b R c , wherein R b and R c each independently represent hydrogen or halo.
• R 1 represents hydrogen, halo or C 1 -C 6 alkyl
• R 4 represents Ci-C 6 alkyl, C 2 - C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -Ci 0 cycloalkyl, Ci-C 6 alkyloxy, C 3 -Ci 0 cycloalkyloxy, (C 3 -Ci O cycloalkyl)Ci-C 3 alkyloxy, (C 3 -C 7 cycloalkyl)C 3 -C 5 alkenyloxy, or (C 3 -C 7 cycloalkyl)C 3 -C 5 alkynyloxy; and Q is selected from the following formulae Q 1 ⁇ to Q 4A :
• R 11 represents hydrogen or hydroxy
• R 15 represents oxygen or CR b R c , wherein R b and R c each independently represent hydrogen or halo; wherein when R 11 is hydrogen, then R 4 is C 2 -C 6 alkynyl, C 3 -Ci 0 cycloalkyloxy, (C 3 -Ci 0 cycloalkyl)Ci-C 3 alkyloxy, (C 3 -C 7 cycloalkyl)C 3 -C 5 alkenyloxy, or (C 3 -C 7 cycloalkyl)C 3 -C 5 alkynyloxy.
• Q is selected from the group consisting of formulae Q 1A to Q 3A .
• compounds of the present invention are selected from:
• the present invention includes the compounds of Formula I and pharmaceutically acceptable salts, prodrugs and/or isotopically labeled compounds thereof, wherein alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl and heteroaryl groups or portions are optionally substituted with one to three suitable substituents as defined above.
• the present invention provides intermediates and processes useful for preparing the intermediates below as well as the compounds of Formula I, and pharmaceutically acceptable salts and prodrugs thereof.
• compounds of the invention can be prepared from other compounds of the invention by elaboration, transformation, exchange and the like of the functional groups present.
• elaboration includes, but is not limited to, hydrolysis, reduction, oxidation, alkylation, acylation, esterification, amidation and dehydration.
• Such transformations can in some instances require the use of protecting groups by the methods disclosed in T. W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 4 th Edition; Wiley: New York, (2007) and PJ. Kocienski, Protecting Groups, 3 rd Edition; Georg Thieme Verlag: Stuttgart, (2005), both of which are incorporated herein by reference.
• Such methods would be initiated after synthesis of the desired compound or at another place in the synthetic route that would be readily apparent to one skilled in the art.
• the present invention provides for synthetic intermediates useful for preparing the compounds of Formula I, and pharmaceutically acceptable salts and prodrugs thereof, according to the general preparative methods discussed below and other processes known to those of skill in the art.
• Inventive compounds of Formula I can be conveniently prepared according to the reaction sequences as shown in Scheme I ( Figure 1).
• acid Al is converted to acid chloride A2 by an acylation agent such as oxalyl chloride, SOCl 2 or POCl 3 , etc.
• Acid chloride A2 is reacted with substituted benzene A3 in the presence of a Lewis acid, such as AlCl 3 OrAlBr 3 , to provide ketone A4.
• the ketone group of intermediate A4 is selectively reduced to methylene with a reducing agent such as Et 3 SiH in the presence of a Lewis acid such as BF 3 » Et 2 0 or TFA.
• Inventive compounds of Formula I can also be conveniently prepared according to a reaction sequence as shown in Scheme II ( Figure 2).
• acid Al 2 is converted to acid chloride Al 3 by an acylation agent such as oxalyl chloride, SOCl 2 or POCl 3 , etc.
• Acid chloride A13 is reacted with substituted benzene A3 in the presence of Lewis acid, such as AlCl 3 OrAlBr 3 , to provide ketone A14.
• the ketone group of intermediate A14 is selectively reduced to methylene with a reducing agent such as Et 3 SiH in the presence of a Lewis acid such as BF 3 ⁇ Et 2 O or TFA, and then deprotection gives the intermediate Al 5.
• Coupling of Al 5 with Al 6 provides intermediate Al 7.
• Oxidation of Al 7 produces intermediate Al 8, which then is deprotected to provide inventive compound Al 9.
• the present invention further provides a pharmaceutical composition
• a pharmaceutical composition comprising an effective amount of a compound or mixture of compounds of Formula I, or a pharmaceutically acceptable salt or prodrug thereof, in a pharmaceutically acceptable carrier.
• a compound of this invention can be incorporated into a variety of formulations for therapeutic administration. More particularly, a compound of the present invention can be formulated into pharmaceutical compositions, together or separately, by formulation with appropriate pharmaceutically acceptable carriers or diluents, and can be formulated into preparations in solid, semi-solid, liquid or gaseous forms, such as tablets, capsules, pills, powders, granules, dragees, gels, slurries, ointments, solutions, suppositories, injections, inhalants and aerosols.
• administration of a compound of the present invention can be achieved in various ways, including oral, buccal, parenteral, intravenous, intradermal (e.g., subcutaneous, intramuscular), transdermal, etc., administration.
• the compound can be administered in a local rather than systemic manner, for example, in a depot or sustained release formulation.
• Suitable formulations for use in the present invention are found in Remington: The Science and Practice of Pharmacy, 21 st Ed., Gennaro, Ed., Lippencott Williams & Wilkins (2003), which is hereby incorporated herein by reference.
• the pharmaceutical compositions described herein can be manufactured in a manner that is known to those of skill in the art, i.e., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
• the following methods and excipients are merely exemplary and are in no way limiting.
• a compound of the present invention is prepared for delivery in a sustained-release, controlled release, extended-release, timed-release or delayed- release formulation, for example, in semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent.
• sustained-release materials have been established and are well known by those skilled in the art.
• Current extended-release formulations include film-coated tablets, multiparticulate or pellet systems, matrix technologies using hydrophilic or lipophilic materials and wax-based tablets with pore- forming excipients ⁇ see, for example, Huang, et al. DrugDev. Ind. Pharm. 29:79 (2003); Pearnchob, et al. DrugDev. Ind. Pharm.
• Sustained-release delivery systems can, depending on their design, release the compounds over the course of hours or days, for instance, over 4, 6, 8, 10, 12, 16, 20, 24 hours or more.
• sustained release formulations can be prepared using naturally-occurring or synthetic polymers, for instance, polymeric vinyl pyrrolidones, such as polyvinyl pyrrolidone (PVP); carboxyvinyl hydrophilic polymers; hydrophobic and/or hydrophilic hydrocolloids, such as methylcellulose, ethylcellulose, hydroxypropylcellulose, and hydroxypropylmethylcellulose; and carboxypolymethylene.
• polymeric vinyl pyrrolidones such as polyvinyl pyrrolidone (PVP); carboxyvinyl hydrophilic polymers
• hydrophobic and/or hydrophilic hydrocolloids such as methylcellulose, ethylcellulose, hydroxypropylcellulose, and hydroxypropylmethylcellulose
• carboxypolymethylene for instance, polymeric vinyl pyrrolidones, such as polyvinyl pyrrolidone (PVP); carboxyvinyl hydrophilic polymers; hydrophobic and/or hydrophilic hydrocolloids,
• the sustained or extended-release formulations can also be prepared using natural ingredients, such as minerals, including titanium dioxide, silicon dioxide, zinc oxide, and clay ⁇ see, U.S. Patent 6,638,521, herein incorporated by reference).
• Exemplified extended release formulations that can be used in delivering a compound of the present invention include those described in U.S. Patent Nos. 6,635,680; 6,624,200; 6,613,361; 6,613,358, 6,596,308; 6,589,563; 6,562,375; 6,548,084; 6,541,020; 6,537,579; 6,528,080 and 6,524,621, each of which is hereby incorporated herein by reference.
• Controlled release formulations of particular interest include those described in U.S.
• Such carriers enable the compounds to be formulated as tablets, pills, dragees, capsules, emulsions, lipophilic and hydrophilic suspensions, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated.
• Pharmaceutical preparations for oral use can be obtained by mixing the compounds with a solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
• Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP).
• disintegrating agents can be added, such as a cross- linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
• compositions which can be used orally include push- fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
• the push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers, hi soft capsules, the active compounds can be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers can be added. All formulations for oral administration should be in dosages suitable for such administration.
• Dragee cores are provided with suitable coatings.
• suitable coatings can be used, which can optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
• Dyestuffs or pigments can be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
• the compounds can be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion.
• the compound can be formulated into preparations by dissolving, suspending or emulsifying them in an aqueous or nonaqueous solvent, such as vegetable or other similar oils, synthetic aliphatic acid glycerides, esters of higher aliphatic acids or propylene glycol; and if desired, with conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifying agents, stabilizers and preservatives.
• a compound of the invention can be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer.
• physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer.
• Formulations for injection can be presented in unit dosage form, e.g., in ampules or in multi-dose containers, with an added preservative.
• the compositions can take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
• compositions for parenteral administration include aqueous solutions of the active compounds in water-soluble form.
• suspensions of the active compounds can be prepared as appropriate oily injection suspensions.
• Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.
• Aqueous injection suspensions can contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
• the suspension can also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
• the active ingredient can be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
• Systemic administration can also be by transmucosal or transdermal means.
• penetrants appropriate to the barrier to be permeated are used in the formulation.
• the agents are formulated into ointments, creams, salves, powders and gels.
• the transdermal delivery agent can be DMSO.
• Transdermal delivery systems can include, e.g., patches.
• penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
• Exemplified transdermal delivery formulations that can find use in the present invention include those described in U.S. Patent Nos. 6,589,549; 6,544,548; 6,517,864; 6,512,010; 6,465,006; 6,379,696; 6,312,717 and 6,310,177, each of which are hereby incorporated herein by reference.
• compositions can take the form of tablets or lozenges formulated in conventional manner.
• a compound of the present invention can also be formulated as a depot preparation.
• Such long acting formulations can be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
• the compounds can be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
• compositions also can comprise suitable solid or gel phase carriers or excipients.
• suitable solid or gel phase carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.
• compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in a therapeutically effective amount.
• the present invention also contemplates pharmaceutical compositions comprising the compounds of Formula I in admixture with an effective amount of other therapeutic agents as combination partners, particularly those used for treating diseases and conditions which can be affected by SGLT inhibition, such as antidiabetic agents, lipid-lowering/lipid- modulating agents, agents for treating diabetic complications, anti-obesity agents, antihypertensive agents, antihyperuricemic agents, and agents for treating chronic heart failure, atherosclerosis or related disorders.
• An effective amount of the compound and/or combination partner will, of course, be dependent on the subject being treated, the severity of the affliction and the manner of administration.
• an efficacious or effective amount of a compound is determined by first administering a low dose or small amount, and then incrementally increasing the administered dose or dosages until a desired therapeutic effect is observed in the treated subject, with minimal or no toxic side effects.
• Applicable methods for determining an appropriate dose and dosing schedule for administration of the present invention are described, for example, in Goodman and Gilman 's The Pharmacological Basis of Therapeutics, 11 th Ed., Brunton, Lazo and Parker, Eds., McGraw-Hill (2006), and in Remington: The Science and Practice of Pharmacy, 21 st Ed., Gennaro, Ed., Lippencott Williams & Wilkins (2003), both of which are hereby incorporated herein by reference.
• the present invention further provides methods of using the compounds of Formula I for the prevention and treatment of disease.
• the invention provides a method of treating type 1 and type 2 diabetes mellitus, hyperglycemia, diabetic complications (such as retinopathy, nephropathy, neuropathy, ulcers, micro- and macroangiopathies, gout and diabetic foot disease), insulin resistance, metabolic syndrome (Syndrome X), hyperinsulinemia, hypertension, hyperuricemia, obesity, edema, dyslipidemia, chronic heart failure, atherosclerosis and related diseases, which comprises administering an effective amount of a compound or mixture of compounds of Formula I, or a pharmaceutically acceptable salt or prodrug thereof, to a subject in need thereof.
• the invention provides a method of using a compound or mixture of compounds of Formula I, or a pharmaceutically acceptable salt or prodrug thereof, for the preparation of a medicament for treating type 1 and type 2 diabetes mellitus, hyperglycemia, diabetic complications, insulin resistance, metabolic syndrome, hyperinsulinemia, hypertension, hyperuricemia, obesity, edema, dyslipidemia, chronic heart failure, atherosclerosis and related diseases.
• the present invention also contemplates the use of the compounds of Formula I, or pharmaceutically acceptable salts or prodrugs thereof, in combination with other therapeutic agents, particularly those used for treating the above-mentioned diseases and conditions, such as antidiabetic agents, lipid-lowering/lipid-modulating agents, agents for treating diabetic complications, anti-obesity agents, antihypertensive agents, antihyperuricemic agents, and agents for treating chronic heart failure, atherosclerosis or related disorders.
• therapeutic agents particularly those used for treating the above-mentioned diseases and conditions, such as antidiabetic agents, lipid-lowering/lipid-modulating agents, agents for treating diabetic complications, anti-obesity agents, antihypertensive agents, antihyperuricemic agents, and agents for treating chronic heart failure, atherosclerosis or related disorders.
• Examples of antidiabetic agents suitable for use in combination with compounds of the present invention include insulin and insulin mimetics, sulfonylureas (such as acetohexamide, carbutamide, chlorpropamide, glibenclamide, glibornuride, gliclazide, glimepiride, glipizide, gliquidone, glisoxepide, glyburide, glyclopyramide, tolazamide, tolcyclamide, tolbutamide and the like), insulin secretion enhancers (such as JTT -608, glybuzole and the like), biguanides (such as metformin, buformin, phenformin and the like), sulfonylurea/biguanide combinations (such as glyburide/metformin and the like), meglitinides (such as repaglinide, nateglinide, mitiglinide and the like), thiazolidinediones (such as
• protein tyrosine phosphatase- IB inhibitors such as KR61639, IDD-3, PTP-3848, PTP-112, OC- 86839, PNU-177496, compounds described in Vats, R.K., et al., Current Science, Vol. 88, No. 2, 25 January 2005, pp.
• glycogen phosphorylase inhibitors such as NN-4201, CP-368296 and the like
• glucose-6-phosphatase inhibitors such as NN-4201, CP-368296 and the like
• fructose 1,6- bisphosphatase inhibitors such as CS-917, MB05032 and the like
• pyruvate dehydrogenase inhibitors such as AZD-7545 and the like
• imidazoline derivatives such as BLl 1282 and the like
• hepatic gluconeogenesis inhibitors such as FR-225659 and the like
• D- chiroinositol glycogen synthase kinase-3 inhibitors (such as compounds described in Vats, R.K., et al., Current Science, Vol.
• incretin mimetics such as exenatide and the like
• glucagon receptor antagonists such as BAY-27-9955, NN-2501, NNC-92-1687 and the like
• glucagon-like peptide-1 GLP-I
• GLP-I analogs such as liraglutide, CJC-1131, AVE-0100 and the like
• GLP-I receptor agonists such as AZM- 134, LY-315902, GlaxoSmithKline 716155 and the like
• amylin, amylin analogs and agonists such as pramlintide and the like
• fatty acid binding protein (aP2) inhibitors such as compounds described in U.S.
• beta-3 adrenergic receptor agonists such as solabegron, CL-316243, L-771047, FR- 149175 and the like
• agents for treating diabetic complications suitable for use in combination with compounds of the present invention include aldose reductase inhibitors (such as epalrestat, imirestat, tolrestat, minalrestat, ponalrestat, zopolrestat, fidarestat, ascorbyl gamolenate, ADN-138, BAL-ARI8, ZD-5522, ADN-311, GP-1447, IDD-598, risarestat, zenarestat, methosorbinil, AL-1567, M-16209, TAT, AD-5467, AS-3201, NZ-314, SG-210, JTT-811, lindolrestat, sorbinil and the like), inhibitors of advanced glycation end- products (AGE) formation (such as pyridoxamine, OPB-9195, ALT-946, ALT-711, pimagedine and the like), AGE breakers (such as ALT-711 and the like), sulodexide,
• antihyperuricemic agents suitable for use in combination with compounds of the present invention include uric acid synthesis inhibitors (such as allopurinol, oxypurinol and the like), uricosuric agents (such as probenecid, sulfinpyrazone, benzbromarone and the like) and urinary alkalinizers (such as sodium hydrogen carbonate, potassium citrate, sodium citrate and the like).
• uric acid synthesis inhibitors such as allopurinol, oxypurinol and the like
• uricosuric agents such as probenecid, sulfinpyrazone, benzbromarone and the like
• urinary alkalinizers such as sodium hydrogen carbonate, potassium citrate, sodium citrate and the like.
• hydroxymethylglutaryl coenzyme A reductase inhibitors such as acitemate
• low density lipoprotein receptor activators such as
• Patent Nos. 5,712,396; 4,924,024; 4,871,721 and the like nicotinic acid derivatives (such as acipimox, nicotinic acid, ricotinamide, nicomol, niceritrol, nicorandil and the like), bile acid sequestrants (such as colestipol, cholestyramine, colestilan, colesevelam, GT- 102-279 and the like), sodium/bile acid cotransporter inhibitors (such as 264W94, S-8921, SD-5613 and the like), and cholesterol ester transfer protein inhibitors (such as torcetrapib, JTT-705, PNU-107368E, SC- 795, CP-529414 and the like).
• nicotinic acid derivatives such as acipimox, nicotinic acid, ricotinamide, nicomol, niceritrol, nicorandil and the like
• anti-obesity agents suitable for use in combination with compounds of the present invention include serotonin-norepinephrine reuptake inhibitors (such as sibutramine, milnacipran, mirtazapine, venlafaxine, duloxetine, desvenlafaxine and the like), norepinephrine-dopamine reuptake inhibitors (such as radafaxine, bupropion, amineptine and the like), serotonin-norepinephrine-dopamine reuptake inhibitors (such as tesofensine and the like), selective serotonin reuptake inhibitors (such as citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline and the like), selective norepinephrine reuptake inhibitors (such as reboxetine, atomoxetine and the like), norepinephrine releasing stimulants (such as rol
• beta-3 adrenergic receptor agonists such as L-796568, CGP 12177, BRL-28410, SR-58611A, ICI-198157, ZD- 2079, BMS-194449, BRL-37344, CP-331679, CP-331648, CP-114271, L-750355, BMS- 187413, SR-59062A, BMS-210285, LY-377604, SWR-0342SA, AZ-40140, SB-226552, D- 7114, BRL-35135, FR-149175, BRL-26830A, CL-316243, AJ-9677, GW-427353, N-5984, GW-2696 and the like), cholecystokinin agonists (such as SR-146131, SSR- 125180, BP- 3.200, A-71623, A-71378, FPL-15849, GI-248573,
• melanin-concentrating hormone receptor antagonists such as GlaxoSmithKline 803430X, GlaxoSmithKline 856464, SNAP-7941, T-226296 and the like (see, e.g., Handlon AL and Zhou H, J. Med. Chem. 2006, 49:4017-4022)
• melanocortin-4 receptor agonists including PT-15, Ro27- 3225, THIQ, NBI 55886, NBI 56297, NBI 56453, NBI 58702, NBI 58704, MB243 and the like (see, e.g., Nargund RP et al., J. Med. Chem.
• selective muscarinic receptor Mi antagonists such as telenzepine, pirenzepine and the like
• opioid receptor antagonists such as naltrexone, methylnaltrexone, nalmefene, naloxone, alvimopan, norbinaltorphimine, nalorphine and the like
• antihypertensive agents and agents for treating chronic heart failure, atherosclerosis or related diseases suitable for use in combination with compounds of the present invention include bimoclomol, angiotensin-converting enzyme inhibitors (such as captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril and the like), neutral endopeptidase inhibitors (such as thiorphan, omapatrilat, MDL- 100240, fasidotril, sampatrilat, GW-660511, mixanpril, SA-7060, E-4030, SLV-306, ecadotril and the like), angiotensin II receptor antagonists (such as candesartan cilexetil, eprosartan, irbesartan, losartan, olmesartan medoxomil, telmisartan, vals
• the invention provides for a pharmaceutical composition
• a pharmaceutical composition comprising effective amounts of a compound or mixture of compounds of Formula I, or a pharmaceutically acceptable salt or prodrug thereof, and at least one member selected from the group of therapeutic agents listed above as combination partners, in a pharmaceutically acceptable carrier.
• the treatment of the present invention can be administered prophylactically to prevent or delay the onset or progression of a disease or condition (such as hyperglycemia), or therapeutically to achieve a desired effect (such as a desired level of serum glucose) for a sustained period of time.
• a disease or condition such as hyperglycemia
• a desired effect such as a desired level of serum glucose
• the compounds of the present invention can be administered to a subject, e.g., a human patient, a domestic animal such as a cat or a dog, independently or together with a combination partner, in the form of their pharmaceutically acceptable salts or prodrugs, or in the form of a pharmaceutical composition where the compounds and/or combination partners are mixed with suitable carriers or excipient(s) in a therapeutically effective amount.
• a subject e.g., a human patient, a domestic animal such as a cat or a dog, independently or together with a combination partner, in the form of their pharmaceutically acceptable salts or prodrugs, or in the form of a pharmaceutical composition where the compounds and/or combination partners are mixed with suitable carriers or excipient(s) in a therapeutically effective amount.
• a compound or mixture of compounds of Formula I, or a pharmaceutically acceptable salt or prodrug thereof, and an additional active agent to be combined therewith can be present in a single formulation, for example a capsule or tablet, or in two separate formulations, which can be the same or different, for example, in the form of a kit comprising selected numbers of doses of each agent.
• the appropriate dosage of compound will vary according to the chosen route of administration and formulation of the composition, among other factors, such as patient response.
• the dosage can be increased or decreased over time, as required by an individual patient.
• a patient initially may be given a low dose, which is then increased to an efficacious dosage tolerable to the patient.
• a useful dosage for adults may be from 1 to 2000 mg, preferably 1 to 200 mg, when administered by oral route, and from 0.1 to 100 mg, preferably 1 to 30 mg, when administered by intravenous route, in each case administered from 1 to 4 times per day.
• a useful dosage of the combination partner may be from 20% to 100% of the normally recommended dose.
• Dosage amount and interval can be adjusted individually to provide plasma levels of the active compounds which are sufficient to maintain therapeutic effect.
• therapeutically effective serum levels will be achieved by administering single daily doses, but efficacious multiple daily dose schedules are included in the invention, hi cases of local administration or selective uptake, the effective local concentration of the drug may not be related to plasma concentration.
• One having skill in the art will be able to optimize therapeutically effective local dosages without undue experimentation.
• Triethylsilane (1 mL, 7.44 mmol, 3 eq) and boron-trifluoride etherate (0.44 mL, 4.96 mmol, 2 eq) were added in that order into a solution of 2 (1.9 g, 2.48 mmol, 1 eq) in CH 2 Cl 2 under argon at -20 0 C, then allowed to react for over 4 hours maintaining a temperature of -20 0 C. NaCl (aq. sat) was added to the quench the reaction. The mixture was extracted with CH 2 Cl 2 (20 mL X 3), and the organic layer was washed with brine, dried over Na 2 SO 4 , filtrated, the filtrate was evaporated to dryness.
• Examples 18 and 19 the structures of compounds synthesized were confirmed using the following procedures: 1 H NMR data were acquired on a Varian Mercury 300 spectrometer at 300 MHz, with chemical shifts referenced to internal TMS. Liquid chromatography electrospray ionization mass spectrometry (LC-ESI-MS) analysis was performed on instrumentation consisting of Shimadzu LC-IOAD vp series HPLC pumps and dual wavelength UV detector, a Gilson 215 autosampler, a Sedex 75c evaporative light scattering (ELS) detector, and a PE/Sciex API 150EX mass spectrometer.
• LC-ESI-MS Liquid chromatography electrospray ionization mass spectrometry
• the ELS detector was set to a temperature of 40 °C, a gain setting of 7, and a N 2 pressure of 3.3 atm.
• the Turbo IonSpray source was employed on the API 150 with an ion spray voltage of 5 kV, a temperature of 300 0 C, and orifice and ring voltages of 5 V and 175 V respectively. Positive ions were scanned in Ql from 160 to 650 m/z. 5.0 ⁇ L injections were performed for each sample, on a Phenomenex Gemini 5 ⁇ m C18 column.
• Diiodomethane (47 ⁇ L, 583 ⁇ mol) was added drop-wise and the resulting mixture was stirred over night. 40% product formation was observed. More dimethyl zinc (18 more equivalent in two batches over 48 hour period) and diiodomethane (35 equivalent in two batches over 48 hour period) were added and the reaction was 80% complete after 96 hours of reaction. Saturated solution OfNH 4 Cl (1 mL) was added and the mixture was stirred for 30 minutes. The mixture was diluted with water (1 mL) and extracted into ethyl acetate (3 x 1 mL).
• Triethylsilane (167.9 g, 229.7 mL, 1.446 mol, 2 eq) and boron-trifluoride etherate (205.2 g, 204.1 mL, 1.446 mol, 2 eq) were successively added into a solution of (lR,4R,5S,6R)-4,5,6-tris(benzyloxy)-3-(benzyloxymethyl)-l-(4-chloro-3-(4- ethylbenzyl)phenyl)cyclohex-2-enol (614.0 g, crude, -0.723 mol, leq) in methylene chloride (2.6 L) under argon at -20 0 C and the mixture stirred over 1 h at -20 0 C.
• the mixture was stirred for 40 min at this temperature.
• the reaction vessel was cooled to room temperature and the contents were transferred to a three-necked flask and cooled to -20 0 C.
• a cold (0 °C) solution of sodium hydroxide (78.1 g, 3 M in water, 1.953 mol, 3 eq) was added, followed by 30% hydrogen peroxide (442.8 g, 438.4 mL, 1.953 mol, 20 eq), and the mixture was allowed to warm to room temperature overnight.
• the reaction mixture was acidified with 1 N hydrochloric acid to pH 6 and the solvent was removed under reduced pressure. Water (5 L) was added into the residue and extracted with ethyl acetate (3 x 2 L).
• This example illustrates the preparation of l-(4-(2-chloro-5-((lR,2S,3R,4R,5S,6R)- 2,3,4,6-tetrahydroxy-5-(hydroxymethyl)cyclohexyl)benzyl)phenyl)ethanone (39).
• Compound 40 was prepared by reduction of (1 S,2R,3R,4S,5R,6R)-4- (acetoxymethyl)-6-(3-(4-acetylbenzyl)-4-chlorophenyl)cyclohexane-l,2,3,5-tetrayl tetraacetate (38) with excess sodium borohydride and purification by preparative HPLC to give 0.6 mg of a clear film.
• (EST): 467 [M+HCOO] '
• a full-length cDNA clone expressing human SGLT2 (GenScript Corporation) was subcloned into Hind III and Not I sites of pEAKl 5 expression vector. Clones harboring the cDNA inserts were identified by restriction analysis.
• Plasmid containing human SGLT2 was linearized with Nsi I and purified by agarose gel electrophoresis. Using Lipofectamine 2000 Transfection Reagent (Invitrogen Corporation), DNA was transfected into HEK293.ETN cells and cultured in Dulbecco's Modified Eagle Medium (DMEM) containing 10% fetal bovine serum (FBS) at 37°C under 5% CO 2 for 24 h. Transfectants were selected in the same growth medium supplemented with puromycin (Invitrogen Corporation) for two weeks. Puromycin-resistant cells were recovered and seeded on a fresh 96-well plate (single cell per well) and cultured in the presence of puromycin until cells became confluent.
• DMEM Dulbecco's Modified Eagle Medium
• FBS fetal bovine serum
• Full-length human SGLTl cDNA on pDream2.1 expression vector was obtained from GenScript Corporation and propagated in Escherichia coli strain DH5 ⁇ using Luria- Bertani (LB) medium containing ampicillin. Plasmid DNA was isolated using the QIAGEN Plasmid Midi Kit (QIAGEN Inc.). Human SGLTl expression plasmid DNA was transfected into COS-7 cells (American Type Culture Collection) using Lipofectamine 2000 Transfection Reagent according to a manufacturer suggested protocol. Transfected cells were stored in DMEM containing 10% dimethyl sulfoxide (DMSO) at -80 °C.
• DMSO dimethyl sulfoxide
• Test compound in 50 ⁇ l each of sodium or sodium- free buffer containing 40 ⁇ Ci/ml methyl- ⁇ -D- [U- 14 C] glucopyranoside (Amersham Biosciences/GE Healthcare) and 25% human serum was added per well of a 96-well plate and incubated at 37 0 C with shaking for either 2 h (SGLTl assay) or 1.5 h (SGLT2 assay).

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Life Sciences & Earth Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Diabetes (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Biochemistry (AREA)
• Biotechnology (AREA)
• Molecular Biology (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Genetics & Genomics (AREA)
• Urology & Nephrology (AREA)
• Child & Adolescent Psychology (AREA)
• Hospice & Palliative Care (AREA)
• Vascular Medicine (AREA)
• Emergency Medicine (AREA)
• Endocrinology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
• Pyrane Compounds (AREA)

Priority Applications (11)

Applications Claiming Priority (2)

Publications (1)

Family

ID=40754059

Family Applications (1)

Country Status (16)

Cited By (9)

Families Citing this family (5)

Citations (3)

Family Cites Families (59)

• 2008
  • 2008-11-12 UA UAA201008620A patent/UA101004C2/uk unknown
  • 2008-12-11 CN CN200880126441.9A patent/CN101938902B/zh not_active Expired - Fee Related
  • 2008-12-11 BR BRPI0819930A patent/BRPI0819930A2/pt not_active IP Right Cessation
  • 2008-12-11 WO PCT/US2008/086472 patent/WO2009076550A1/en not_active Ceased
  • 2008-12-11 NZ NZ586639A patent/NZ586639A/en not_active IP Right Cessation
  • 2008-12-11 EP EP08859426.2A patent/EP2230907B1/en active Active
  • 2008-12-11 TW TW097148259A patent/TWI426081B/zh not_active IP Right Cessation
  • 2008-12-11 JP JP2010538165A patent/JP5507464B2/ja not_active Expired - Fee Related
  • 2008-12-11 US US12/333,190 patent/US8129434B2/en not_active Expired - Fee Related
  • 2008-12-11 KR KR1020107015420A patent/KR101567969B1/ko not_active Expired - Fee Related
  • 2008-12-11 CA CA2707909A patent/CA2707909C/en not_active Expired - Fee Related
  • 2008-12-11 AU AU2008335080A patent/AU2008335080B2/en not_active Ceased
  • 2008-12-11 RU RU2010128940/04A patent/RU2505521C2/ru not_active IP Right Cessation
  • 2008-12-12 AR ARP080105417A patent/AR071268A1/es not_active Application Discontinuation
• 2010
  • 2010-06-07 IL IL206234A patent/IL206234A0/en unknown
  • 2010-06-22 ZA ZA2010/04400A patent/ZA201004400B/en unknown
• 2018
  • 2018-02-21 AR ARP180100403A patent/AR113211A2/es unknown

Patent Citations (3)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events